CD25
Showing 1 - 25 of 9,000
The Effecacy and Safety of Humanized CD25 Antibody in aGVHD Prophylaxis Among Elderly Patients After HID-HSCT Trial (CD25
Not yet recruiting
- The Effecacy and Safety of Humanized CD25 Antibody in aGVHD Prophylaxis Among Elderly Patients After HID-HSCT
- CD25 prophylaxis
- (no location specified)
Jun 20, 2023
Safety and Efficacy Trial in Suzhou (Basiliximab, Vedolizumab)
Recruiting
- Safety and Efficacy
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Sep 27, 2023
Tregs CD25 CXCL9 in Vitiligo
Not yet recruiting
- Vitiligo
- +3 more
- ELIZA , Flowcytometry
- (no location specified)
Oct 3, 2022
![](/image/sponsor/kazakhstan's_medical_university_"ksph")
Health Status of Children Born After Assisted Reproductive
Recruiting
- Children Born After Assisted Reproductive Technologies
- +2 more
- hemogram examination
-
Almaty, KazakhstanSevara ilmuratova
Oct 17, 2023
Haematological Malignancies Trial in London, Manchester (CD25/71 allodepleted donor T-cells)
Completed
- Haematological Malignancies
- CD25/71 allodepleted donor T-cells
-
London, United Kingdom
- +1 more
Jul 18, 2022
Liver Transplant Trial in Boston (biological, procedure, drug)
Recruiting
- Liver Transplant
- arTreg-CSB
- +4 more
-
Boston, MassachusettsMassachusetts General Hospital: Transplantation
Jan 30, 2023
Interleukins in Periodontal Disease Progression
Recruiting
- Periodontitis
- Gingivitis
- Flow Cytometric Detection of Regulatory T Cells and Cytokines analysis by ELISA
-
Assiut, Asyut, EgyptDepartment of oral medicine, Periodontology, Oral diagnosis and
Nov 16, 2023
Late Complication From Kidney Transplant Trial in San Francisco (Treg infusion)
Completed
- Late Complication From Kidney Transplant
- Treg infusion
-
San Francisco, CaliforniaUniversity of California, San Francisco
Jul 11, 2022
Liver Transplant Trial in San Francisco (biological, procedure, drug)
Recruiting
- Liver Transplant
- arTreg
- +4 more
-
San Francisco, CaliforniaUniversity of California, San Francisco
Sep 13, 2022
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in Duarte (procedure, biological, drug,
Recruiting
- Acute Lymphoblastic Leukemia
- +3 more
- Allogeneic Hematopoietic Stem Cell Transplantation
- +8 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jan 12, 2023
Hairy Cell Leukemia Trial run by the NCI (Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin)
Active, not recruiting
- Hairy Cell Leukemia
- Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Apr 13, 2022
Acute Respiratory Distress Syndrome Due to Disease Caused by 2019-nCoV Trial in Chapel Hill, Columbus (Cryopreserved Ex Vivo
Recruiting
- Acute Respiratory Distress Syndrome Due to Disease Caused by 2019-nCoV
- Cryopreserved Ex Vivo Expanded Polyclonal CD4+CD127lo/-CD25+ T Regulatory Cells
-
Chapel Hill, North Carolina
- +1 more
Oct 15, 2021
Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Duarte (Basiliximab, Carmustine, Cytarabine)
Recruiting
- Recurrent Hodgkin Lymphoma
- Refractory Hodgkin Lymphoma
- Basiliximab
- +6 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jun 16, 2022
Parkinson Disease Trial in Rome (Standard LD/CD, Semi continuous intra-oral administration of LD/CD)
Completed
- Parkinson Disease
- Standard LD/CD
- Semi continuous intra-oral administration of LD/CD
-
Rome, ItalyIrccs San Raffaele Pisana
Oct 17, 2022
Safety and Efficacy Trial in Suzhou (Ruxolitinib)
Recruiting
- Safety and Efficacy
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Aug 23, 2021
Hodgkin Disease, Hodgkin Lymphoma Trial run by the NCI (procedure, drug, radiation)
Terminated
- Hodgkin Disease
- Hodgkin Lymphoma
- Auto stem cell transplant
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Sep 16, 2021
Type 1 Diabetes Trial in San Francisco, New Haven (PolyTregs+IL-2)
Completed
- Type 1 Diabetes Mellitus
- PolyTregs+IL-2
-
San Francisco, California
- +1 more
Oct 15, 2021
Lymphoma Trial (68Ga-NOTA-RP25)
Not yet recruiting
- Lymphoma
- 68Ga-NOTA-RP25
- (no location specified)
Dec 16, 2021
GVHD Trial in Stanford (donor regulatory T lymphocytes, laboratory biomarker analysis)
Suspended
- Graft Versus Host Disease
- donor regulatory T lymphocytes
- laboratory biomarker analysis
-
Stanford, CaliforniaStanford University Hospitals and Clinics
Aug 18, 2021
CD19+ Relapse/Refractory B-ALL Trial in Beijing (CAR-T-19 Cells)
Recruiting
- CD19+ Relapse/Refractory B-ALL
- CAR-T-19 Cells
-
Beijing, Beijing, ChinaChinese PLA General Hospital
Feb 26, 2022
Pemphigus Foliaceus, Pemphigus Vulgaris Trial in United States (Cohort 1: 1.0 x 10^8 PolyTregs, Cohort 2: 2.5x10^8 PolyTregs)
Active, not recruiting
- Pemphigus Foliaceus
- Pemphigus Vulgaris
- Cohort 1: 1.0 x 10^8 PolyTregs
- Cohort 2: 2.5x10^8 PolyTregs
-
San Francisco, California
- +3 more
Oct 22, 2021
Recurrent Adult Hodgkin Lymphoma Trial in Duarte (biological, drug, other, procedure)
Active, not recruiting
- Recurrent Adult Hodgkin Lymphoma
- basiliximab
- +8 more
-
Duarte, CaliforniaCity of Hope Medical Center
Mar 17, 2022
Leukemia, Myeloid, Chronic, AML, Leukemia, Lymphocytic, Acute Trial in Minneapolis (biological, drug, radiation)
Terminated
- Leukemia, Myeloid, Chronic
- +8 more
- Stem Cell Transplant
- +5 more
-
Minneapolis, MinnesotaMasonic Cancer Center, University of Minnesota
Dec 31, 2020
Advanced Solid Tumors With Literature Evidence of CD25(+) Treg Content, Head Neck Cancer Squamous Cell Carcinoma, NSCLC Trial in
Recruiting
- Advanced Solid Tumors With Literature Evidence of CD25(+) Treg Content
- +12 more
- ADCT-301
- Pembrolizumab
-
Palo Alto, California
- +9 more
Mar 24, 2022